Orthobiologics Market

This study intends to unfurl the multiple facets of global orthobiologics market and thereby examine how the short-term growth of the market will unfold during the stipulated time span.

Soaring Prevalence of Bone-related Injuries Create a Strong Base of Expansion for Orthobiologics Market

The rise in the frequency of sports injuries, as well a growing number of road accidents remain the prime factors anticipated to propel the growth of global orthobiologics market during the forecast period. Furthermore, it is projected that the market for orthobiologics will grow due to the rise in spinal diseases, and disorders. In terms of musculoskeletal problems, low back pain, which affects more than half a billion people globally, is the most common cause of disability. Additionally, it is predicted that the growing patient desire for minimally invasive procedures will restrain the expansion of the orthobiologics market.

Growing elderly population, who are more prone to spinal and other orthopedic problems, is another factor boosting the demand for orthopedic surgeries, thereby bolstering the expansion of orthobiologics market. The rising prevalence of various bone illnesses, such as bone infections (osteomyelitis), and bone malignancies, is one of the major driving factors (malignant and benign) for market. In addition to these, several other situations and conditions call for the administration of biologics. These ailments include basic and complicated trauma, bone lesions, and bone fractures. In such circumstances, orthopedic biologic solutions frequently serve as the best therapy for repairing bone abnormalities, promoting orthobiologics market expansion.

Augmenting R&D Investments Largely Favour Orthobiologics Market Growth

The growing use of allografts made of stem cells in various orthopedic operations is another factor contributing toward the  eestimated growth of orthobiologics market. Furthermore, it is anticipated that increasing R&D investments and collaborations by well-known medical device and biotechnology businesses, which will lead to advanced orthobiologics, will broaden the orthobiologics industry's support base. In addition, developing nations will likely present additional chances for the orthobiologics market to expand in the years to come. A few of the market participants are also concentrating on introducing antibiotic-eluting bone void fillers to treat bone disorders, promoting market expansion overall. Additionally, a healthy pipeline of orthobiologics industry participants is anticipated to support market expansion over time. In April 2020, Biocomposites said that its STIMULAN product line had received a new CE Mark approval for the combination of antibiotics such as vancomycin, tobramycin, and gentamicin in bone void fillers, which can be utilized as a therapy option in the management of infected bone and soft tissues.

Orthobiologics Market: COVID-19 Impact

With the decreasing patient volume, the COVID-19 epidemic has negatively influenced the market for orthobiologic products. During the COVID-19 epidemic, certain prominent industry firms saw significant revenue declines. The reallocation of healthcare resources, decreased patient visits to emergency care and outpatient settings, and supply chain issues hampered orthobiologics sales globally, particularly in the first six months of 2020. In terms of sales, the global market fell -by 10.6% in 2020 vs. 2019. However, the increase in patient volume was still lower than in 2019. In the United States, patient volume recovered in 2021. Higher vaccination coverage among the general population and the implementation of strict guidelines and COVID-19 protocols in public spaces were credited to the recovery of patient volume in 2021.

Increased Orthopedic Injury Cases to Support Orthobiologics Market Growth

The key factor most likely to drive up demand for orthobiologic products during the forecast period is a significant increase in the frequency of orthopedic injuries and musculoskeletal illnesses that cause excruciating physical pain and restricted mobility. For instance, more than 6.8 million individuals with orthopedic injuries seek medical care each year in the United States, according to statistics from the American Academy of Orthopedic Surgeons. This sizable patient base needing orthopedic injury therapy could accelerate orthobiologics market expansion in the upcoming years. A significant increase in osteoporosis illness, characterized by a low bone-to-mass ratio and a physical weakening of bone tissues, is also to blame for the rising incidence of hip and backbone fractures. It is projected that this aspect will fuel market growth in the upcoming years.

Increase in Rate of Sports Injuries to Fuel Orthobiologics Market

Athletes now have a lot of anxiety about sports injuries. Sports injuries involve the musculoskeletal system, which comprises the muscles, tendons, ligaments, fascia, nerves, bones, and tissues. The main causes of these injuries include falls, overexertion, and fractures. Most sports-related injuries and muscle injuries affect the lower and upper extremities. Orthobiologics, like stem cells, are employed to treat frequent, severe, and persistent sports injuries. The most important factor contributing to the rise in injuries among young people is year-round participation in a single activity. The most common sports involved in hand injuries include handball, rugby, combat sports, field hockey, and basketball.

Bone Morphogenetic Proteins, and Clinical Limitations Continue to Hamper Orthobiologics Market Growth

The only bone morphogenetic protein on the market is INFUSE from Medtronic. After the U.S. FDA approved this product's usage in spinal fusion surgeries in 2002, it experienced tremendous growth in popularity. But a few years following INFUSE's approval, Medtronic's BMP has come under renewed criticism. The off-label use of INFUSE and major problems with the medicine have prompted this examination. INFUSE, for instance, may cause major adverse reactions such as infections, urinary issues, bone and nerve damage, male sterility, and possibly an increased risk of cancer. Such negative effects linked to this product are anticipated to hinder its sales, consequently restricting the total market growth. Additionally, the market expansion is anticipated to be constrained by bone graft substitutes with some clinical limitations, such as unfavorable tissue reaction, partial or absent bone formation, and infection of both soft tissue and bone.

Viscosupplementation to Dominate Orthobiologics Market

In the forecast period, viscosupplementation dominated the orthobiologics industry. A significant proportion is related to the widespread availability and extraordinary adoption of these medicines in conditions including osteoarthritis and hip degenerative joint degeneration. The advantages of viscosupplementation are thought to cause a high adoption rate. These advantages include improved knee mobility, pain relief, reduced invasiveness, and fewer adverse effects. It is also assumed that this is due to the great demand for minimally invasive surgical treatments and the patient population's high acceptability of these techniques. Improvements are aiding the expansion of this market in reimbursement policies for viscosupplements. Another reason supporting the largest shares of the segment is the introduction of new manufacturers and recent market approvals.

Orthobiologics Market Gains Momentum Across Spinal Fusion Sector

A majority share of more than 50% in the application category was accounted for by spinal fusion. With their capacity to deliver high bone stability and quick bone healing while alleviating long-term spinal diseases, demineralized bone matrices, bone morphogenetic proteins, autografts, and allografts have consistently gained a dominant share in spinal fusion surgery. The category has a sizable market share with increased spinal fusion operations worldwide. Furthermore, it is anticipated that the segmental growth will be boosted in the upcoming years by important firms with a broad product portfolio of orthobiologic products for the application field of spinal fusion surgeries and growing approvals for new products. Most spinal cord injuries result from preventable events like vehicle accidents, falls, or violent crimes. Injury to the spinal column's bony, ligamentous, or neurological structures results in traumatic spinal injury (TSI), which is associated with considerable morbidity and mortality.

Massive Growth in Road Accident Cases Continues to Account for North America’s Lead in Orthobiologics Market

Region-wise, North America held the largest share in orthobiologics market in 2020. Growing rates of sports injuries and auto accidents, osteoarthritis incidence, an aging and obese population, and an increase in the use of minimally invasive surgery are the main reasons propelling the growth of the North America’s orthobiologics market. Rising product launches and strategic moves by important market participants may also support market expansion. According to a Canadian study of 2029 teenagers published in July 2021, 889 of the 1,971 participants reported experiencing an injury in the previous year, with an incidence rate of about 45.10 per 100 students. The study concluded that highschool students experienced a high incidence of injuries related to sports and recreational activities, with 29% of teenagers reporting experiencing an injury that required medical attention. As a result of the aforementioned factors, it is anticipated that the investigated market will experience considerable expansion throughout the study period.

The Asia Pacific orthobiologics market is anticipated to experience a greater share of the worldwide market over the forecast period due to the rising patient population and developing nations like China and India. By 2050, it is anticipated that Asia will account for more than half of all osteoporotic hip fractures worldwide. Increased physician awareness of the benefits of these products and growing healthcare expenditures are the main drivers of the Asia Pacific region's growth of the orthobiologics market. There is a chance for the major companies to invest as the Asia Pacific nations expand. In addition to the improved quality of the healthcare infrastructure, this region's orthobiologics industry is expanding rapidly. Aside from the rising number of product launches in this market, the competition among the major players is intensifying, which substantially impacts ortho biologics leadership in the sector's growth.

Global Orthobiologics Market: Competitive Landscape

In October 2021, AlloSource, one of the largest allograft providers in the United States, announced the release of AlloMend Extra-Large (XL) Acellular Dermal Matrix (ADM), the company's newest product. The AlloMend XL ADM dermal transplant is the company's largest dermal graft. It is available in mesh and non-mesh versions with a 320cm2 (16cm x 20cm) footprint for use in demanding soft tissue applications. In June 2021, Bioventus, a global pioneer in orthobiologic solutions, is introducing a new strip format for its SIGNAFUSE Bioactive Bone Graft. The strips, which contain 55% bioglass by weight, have been proven to produce higher levels of osteoblast development than conventional synthetic bone graft strips. They are available in various lengths ranging from 25 to 200 millimeters, with the longer strips ideal for large, multilayer processes.

A few of the players in the orthobiologics market include Alphatec Spine, Inc., Arthrex, Bioventus, DePuy Synthes, Exactech, Inc., Globus Medical, Inc., Integra Life Sciences, Johnson & Johnson, Medtronic plc, MTF Biologics, RTI Surgical, Inc., Sanofi, Stryker, and Zimmer Biomet.

Regional Classification of the Global Orthobiologics Market is Listed Below:

North America

• U.S.
• Canada

Europe

• Germany
• France
• Spain
• U.K.
• Italy
• Russia
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Southeast Asia
• Rest of Asia Pacific

 Latin America

• Brazil
• Mexico
• Rest of Latin America

Middle East and Africa

• GCC
• South Africa
• Rest of Middle East & Africa

*Regions and countries are subject to change based on data availability.

Key Elements Included In The Study: Global Orthobiologics Market

• Orthobiologics Market by Product/Technology/Grade, Application/End-user, and Region
• Executive Summary (Opportunity Analysis and Key Trends)
• Historical Market Size and Estimates, Value, 2018 - 2022
• Market Value at Regional and Country Level, 2023 - 2030
• Market Dynamics and Economic Overview
• Market Size in Value, Growth Rates, and Forecast Figures, 2023 - 2030
• Competitive Intelligence with Financials, Key Developments, and Portfolio of Leading Companies 
• Regional and Product/Grade/Application/End-user Price Trends Analysis
• Value Chain and Five Force’s Analysis
• Regional/Sub-region/Country Market Size and Trend Analysis
• Company Market Share Analysis and Key Player Profiles

Post Sale Support, Research Updates & Offerings

We value the trust shown by our customers in Fairfield Market Research. We support our clients through our post sale support, research updates and offerings.

• The report will be prepared in a PPT format and will be delivered in a PDF format.

• Additionally, Market Estimation and Forecast numbers will be shared in Excel Workbook.

• If a report being sold was published over a year ago, we will offer a complimentary copy of the updated research report along with Market Estimation and Forecast numbers within 2-3 weeks’ time of the sale.

• If we update this research study within the next 2 quarters, post purchase of the report, we will offer a Complimentary copy of the updated Market Estimation and Forecast numbers in Excel Workbook.

• If there is a geopolitical conflict, pandemic, recession, and the like which can impact global economic scenario and business activity, which might entirely alter the market dynamics or future projections in the industry, we will create a Research Update upon your request at a nominal charge.